Neurological Surgery Doctors in Rochester, MN Accepting Medicare

68 Neurological Surgery doctors found. Showing 61 - 68

Mr. Nitesh Prakashbhai Patel, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Georgios Michalopoulos, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Edward S Ahn, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Vaishnavi Lakshminarasimha Rao, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Charbel Moussalem, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-441-0787

Jamie J Vangompel, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Dr. Damiano Giuseppe Barone, MD, PHD, FRCS Neurological Surgery Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Dr. Christoph Wipplinger, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

News Archive

WHO tackles the parasitic disease Leishmaniasis in Afghanistan

A rapid intervention by the World Health Organization and its partners, the Massoud Foundation and HealthNet International, in Kabul, Afghanistan, made possible by a donation from the Belgian government, should dramatically reduce the incidence of leishmaniasis in less than two years.

Diet low in fermented carbs improves quality of life for patients with IBD

A new study has found that the FODMAP diet can improve gut symptoms and quality of life among patients with inflammatory bowel disease (IBD) in just one month.

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

Health officials announce physician quiz campaign to help reduce medical errors

HHS and other health officials on Monday announced a new campaign designed to limit surgical complications by encouraging patients to quiz their doctors about medical procedures, CQ HealthBeat reports.

Read more Medical News

› Verified 2 days ago

• 1
• 2
• 3
• 4(current)